Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Rhea-AI Summary

Enliven Therapeutics, Inc. (ELVN) will host a webcast to discuss initial proof of concept data on ELVN-001, a small molecule kinase inhibitor for chronic myeloid leukemia (CML). The event features leading CML investigators and management, highlighting the Phase 1a data and treatment paradigm in CML.

BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape. ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML.

The event will feature leading CML investigators and hematology care experts, Professor Michael Mauro, M.D., from Memorial Sloan Kettering Cancer Center, and Professor Fabian Lang, M.D., from Goethe University Hospital, along with the management of Enliven Therapeutics. The discussion will cover ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in CML, and how ELVN-001 could fit into the CML landscape.

The event will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com/. To participate in the live event, please register using this link. An archived webcast will be available following the event.

About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help people with cancer not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

Contact:
Investors
ir@enliventherapeutics.com

Media
media@enliventherapeutics.com

FAQ

What is Enliven Therapeutics, Inc. focused on?

Enliven Therapeutics, Inc. is a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors.

What is ELVN-001?

ELVN-001 is a highly selective, small molecule kinase inhibitor designed to target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML.

Who will be participating in the webcast?

Leading CML investigators and hematology care experts, Professor Michael Mauro, M.D., and Professor Fabian Lang, M.D., along with the management of Enliven Therapeutics.

Where can the webcast be accessed?

The webcast can be accessed by visiting the investor relations section of Enliven Therapeutics' website at https://ir.enliventherapeutics.com/.

How can one participate in the live event?

To participate in the live event, registration is required using the provided link.